Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

Ten patients with recurrent malignant primary brain neoplasms were treated with adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). Nine patients had supratentorial glioma and they received multiple intratumoral instillations of LAK cells through reservoir-...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 1996-02, Vol.27 (2), p.133-140
Main Authors: SANKHLA, S. K, NADKARNI, J. S, BHAGWATI, S. N
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antineoplastic agents
Biological and medical sciences
Brain Neoplasms - diagnostic imaging
Brain Neoplasms - therapy
Child
Child, Preschool
Female
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Interleukin-2 - therapeutic use
Killer Cells, Lymphokine-Activated - immunology
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Recurrence, Local - therapy
Pharmacology. Drug treatments
Recombinant Proteins - therapeutic use
Tomography, X-Ray Computed
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ten patients with recurrent malignant primary brain neoplasms were treated with adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). Nine patients had supratentorial glioma and they received multiple intratumoral instillations of LAK cells through reservoir-catheter system or burrhole. The other patients with disseminated subarachnoid metastases from posterior fossa medulloblastoma received immunotherapy via lumbar subarachnoid route. A partial and transient clinical response was observed in two patients. following the therapy, and a cystic transformation of the essentially solid tumour was noted on the CT scans of these two patients. No significant clinical or radiological response to the treatment was observed in the remaining 8 patients. The results of this preliminary study reveal limitations of the regional intratumoral adoptive immunotherapy using currently available techniques and provide sufficient evidence of its effectiveness to warrant further investigations.
ISSN:0167-594X
1573-7373
DOI:10.1007/bf00177476